FDA Approved: OCREVUS ZUNOVO — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for OCREVUS ZUNOVO (ocrelizumab and hyaluronidase) from Genentech, expanding administration options for multiple scleros…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis
• Relapsing Forms of Multiple Sclerosis

Drugs mentioned

• OCREVUS ZUNOVO (ocrelizumab and hyaluronidase)

Snippet

SUPPL AP for OCREVUS ZUNOVO (OCRELIZUMAB AND HYALURONIDASE)